BACKGROUND: Biliary tract cancer (BTC) has a poor prognosis, in part related to difficulties in diagnosis. Cytokeratin 19 (CK19) is a constituent of the intermediate filament proteins of epithelial cells. CK19 fragments (CYFRA 21-1) are rarely identified in the blood of healthy individuals. We assessed the utility of CYFRA 21-1 as a diagnostic and prognostic marker of BTC. METHODS: Blood was prospectively collected from patients with benign biliary disease (n = 39), primary sclerosing cholangitis (n = 19), PSC-related cholangiocarcinoma (n = 6) and sporadic BTC (n = 60). CYFRA 21-1 levels were measured in duplicate by ELISA. RESULTS: CYFRA 21-1 (≥ 1.5 ng/mL) had a sensitivity of 56% and specificity of 88%, compared with figures of 79% and 78% for CA 19-9 (≥ 37U/mL). Using a higher cut-off of 3 ng/mL, CYFRA 21-1 had a sensitivity of 30% and specificity of 97%. Combination of CYFRA 21-1 (≥ 1.5 ng/mL) and CA 19-9 (≥ 37 U/mL) resulted in sensitivity and specificity of 45% and 96%. In contrast to CA 19-9, CYFRA 21-1 (≥ 3.0 ng/mL) alone was a strong predictor of prognosis (median survival 2 months vs 10 months, p = 0.001). CONCLUSION: Elevated circulating CYFRA 21-1 is a specific, but less sensitive diagnostic marker than CA 19-9, predicts a poor outcome and may act as a surrogate marker of circulating tumor cells in BTC. Further prospective studies of its utility in assessing operability and response to chemotherapy are needed.
BACKGROUND:Biliary tract cancer (BTC) has a poor prognosis, in part related to difficulties in diagnosis. Cytokeratin 19 (CK19) is a constituent of the intermediate filament proteins of epithelial cells. CK19 fragments (CYFRA 21-1) are rarely identified in the blood of healthy individuals. We assessed the utility of CYFRA 21-1 as a diagnostic and prognostic marker of BTC. METHODS: Blood was prospectively collected from patients with benign biliary disease (n = 39), primary sclerosing cholangitis (n = 19), PSC-related cholangiocarcinoma (n = 6) and sporadic BTC (n = 60). CYFRA 21-1 levels were measured in duplicate by ELISA. RESULTS: CYFRA 21-1 (≥ 1.5 ng/mL) had a sensitivity of 56% and specificity of 88%, compared with figures of 79% and 78% for CA 19-9 (≥ 37U/mL). Using a higher cut-off of 3 ng/mL, CYFRA 21-1 had a sensitivity of 30% and specificity of 97%. Combination of CYFRA 21-1 (≥ 1.5 ng/mL) and CA 19-9 (≥ 37 U/mL) resulted in sensitivity and specificity of 45% and 96%. In contrast to CA 19-9, CYFRA 21-1 (≥ 3.0 ng/mL) alone was a strong predictor of prognosis (median survival 2 months vs 10 months, p = 0.001). CONCLUSION: Elevated circulating CYFRA 21-1 is a specific, but less sensitive diagnostic marker than CA 19-9, predicts a poor outcome and may act as a surrogate marker of circulating tumor cells in BTC. Further prospective studies of its utility in assessing operability and response to chemotherapy are needed.
Authors: Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé Journal: J Hepatol Date: 2002-03 Impact factor: 25.083
Authors: J J W Tischendorf; M Krüger; C Trautwein; N Duckstein; A Schneider; M P Manns; P N Meier Journal: Endoscopy Date: 2006-04-27 Impact factor: 10.093
Authors: T G Ntouroupi; S Q Ashraf; S B McGregor; B W Turney; A Seppo; Y Kim; X Wang; M W Kilpatrick; P Tsipouras; T Tafas; W F Bodmer Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640
Authors: M Takada; N Masuda; E Matsuura; Y Kusunoki; K Matui; K Nakagawa; T Yana; I Tuyuguchi; I Oohata; M Fukuoka Journal: Br J Cancer Date: 1995-01 Impact factor: 7.640
Authors: J-L Pujol; O Molinier; W Ebert; J-P Daurès; F Barlesi; G Buccheri; M Paesmans; E Quoix; D Moro-Sibilot; M Szturmowicz; J-M Bréchot; T Muley; J Grenier Journal: Br J Cancer Date: 2004-06-01 Impact factor: 7.640
Authors: Alexander Baraniskin; Stefanie Nöpel-Dünnebacke; Brigitte Schumacher; Christian Gerges; Thilo Bracht; Barbara Sitek; Helmut E Meyer; Guido Gerken; Alexander Dechene; Jörg F Schlaak; Roland Schroers; Christian Pox; Wolff Schmiegel; Stephan A Hahn Journal: Dig Dis Sci Date: 2014-01-31 Impact factor: 3.199
Authors: Banchob Sripa; Paul J Brindley; Jason Mulvenna; Thewarach Laha; Michael J Smout; Eimorn Mairiang; Jeffrey M Bethony; Alex Loukas Journal: Trends Parasitol Date: 2012-09-01